Scientists at King's College London have made a breakthrough in the fight against Alzheimer's disease with the discovery of a new drug that targets multiple aspects of the condition. The experimental treatment, known as KCL-286, has already completed Phase 1 human safety and tolerability trials and has shown promising results in a mouse model of Alzheimer's disease. KCL-286 works by activating a protein involved in the retinoic acid pathway, a biological system associated with how the body processes and uses vitamin A. This pathway is linked to several essential biological processes, including cellular development, gene regulation, and nervous system function. The drug has been found to repair DNA double-strand breaks, which are a type of serious DNA damage that can disrupt normal cellular activity and threaten cell survival. The researchers believe that targeting multiple aspects of Alzheimer's disease, including DNA damage and inflammation, could offer a more effective approach to treating the condition. KCL-286 has already demonstrated an ability to promote the repair of DNA double-strand breaks in earlier research involving neuropathic pain, a type of pain caused by damage or dysfunction in the nervous system. The discovery of KCL-286 is significant because it offers a potential new approach to tackling Alzheimer's disease, which is a complex and multifaceted condition. While many treatments have focused on removing amyloid-beta and tau proteins, which are associated with the disease, KCL-286 targets other biological processes that can contribute to the condition. The researchers are now planning further studies to determine whether KCL-286 can safely slow disease progression or improve outcomes in patients with Alzheimer's disease. If successful, this could lead to a new treatment option for people living with the condition.